Table 3.
Characteristics of 36 NSCLC Patients Treated With Osimertinib with Serial Echocardiography Monitoring
| All (N = 36) | Non-CTRCD (n = 32) | CTRCD (n = 4) | |
|---|---|---|---|
| Age, yrs | 68 (63–74) | 68 (63–74) | 68 (55–76) |
| Females | 26 (72.2) | 22 (68.8) | 4 (100) |
| Smoking | 12 (33.3) | 10 (34.3) | 2 (50) |
| Medical history | |||
| Hypertension | 17 (47.2) | 15 (46.9) | 2 (50) |
| Diabetes mellitus | 1 (2.8) | 0 | 1 (25) |
| Dyslipidemia | 5 (13.9) | 5 (15.6) | 0 |
| Hyperuricemia | 1 (2.8) | 1 (3.1) | 0 |
| Atrial fibrillation | 2 (5.6) | 2 (6.2) | 0 |
| Vasospastic angina | 1 (2.8) | 1 (3.1) | 0 |
| Thoracic aortic aneurysm | 1 (2.8) | 0 | 1 (25) |
| Atrial septal defect | 1 (2.8) | 1 (3.1) | 0 |
| Valvular disease (moderate or greater) | 4 (11.1) | 3 (3.9) | 1 (25) |
| Medication | |||
| Beta-blocker | 2 (5.6) | 1 (3.1) | 1 (25) |
| CCB | 9 (25) | 8 (25.0) | 1 (25) |
| ACE inhibitor | 0 | 0 | 0 |
| ARB | 8 (22.2) | 6 (18.8) | 2 (50) |
| MRA | 1 (2.8) | 1 (3.1) | 0 |
| Loop diuretic | 1 (2.8) | 1 (3.1) | 0 |
Values are median (interquartile range) or n (%).
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; CCB = calcium channel blocker; CTRCD = cancer therapeutics-related cardiac dysfunction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist.